Time-Restricted Feeding Reduces Obesity and Improves Metabolic Health in Rodent Models
December 22, 2025 /
Time-Restricted Feeding / Metabolic Health / Obesity Treatment / Insulin Sensitivity / Rodent Study
Time-restricted feeding (TRF) in rodent models reduces obesity and improves metabolic health by enhancing glucose metabolism, insulin sensitivity, and lipid profiles. Feeding timing significantly influences energy balance, though outcomes vary by diet, duration, and genetic factors.
FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers
December 22, 2025 / Obesity Management / Employer Healthcare / GLP-1 Medication / Cardiometabolic Care / FlyteHealth Program
FlyteHealth is expanding access to Eli Lilly’s obesity medications for self-insured employers, pairing them with its AI-driven, evidence-based cardio-kidney-metabolic care model to improve outcomes, medication adherence, and long-term cost efficiency for obesity and related conditions.
Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial
December 19, 2025 / PCOS Treatment / Metabolic Syndrome / Combined Oral Contraceptives / Metformin Therapy / Hyperandrogenic PCOS
The COMET-PCOS randomized trial found that low-dose combined oral contraceptives effectively managed hyperandrogenic PCOS symptoms in overweight or obese women without increasing metabolic syndrome risk, performing similarly to metformin or combination therapy.
Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation
December 19, 2025 / Time-Restricted Feeding / Rodent Obesity Models / Glucose Tolerance / Insulin Sensitivity / Lipid Profile
Time-restricted feeding (TRF) in rodent obesity models significantly reduced body weight and cholesterol while improving glucose tolerance and insulin sensitivity. A 10-hour feeding window over 8 weeks in C57BL/6 mice was identified as the most effective regimen.
Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation
Time-restricted feeding (TRF) in rodent obesity models consistently improved metabolic health by reducing body weight and cholesterol while enhancing glucose tolerance and insulin sensitivity. A 10-hour feeding window over 8 weeks in C57BL/6 mice proved most effective.
Unwinding how feeding and autonomic signals affect metabolic disease
December 18, 2025 / Serotonin / Feeding Regulation / Metabolic Disease / Obesity Treatment / Autonomic Signals
Dr. Katsunori Nonogaki’s research reveals how serotonin signaling and autonomic pathways regulate feeding, metabolism, and obesity. His work has advanced therapies for metabolic diseases and led to novel inventions targeting vagal nerve activity and serotonin-driven fat accumulation.
Chrononutrition Explained: Why When You Eat Matters for Metabolic Health
December 16, 2025 / Chrononutrition / Circadian Rhythm / Metabolic Health / Late Eating / Glucose Control
Chrononutrition explores how meal timing affects circadian rhythms and metabolic health. Aligning food intake with biological clocks improves glucose regulation, lipid metabolism, and sleep, while late-night eating disrupts metabolic homeostasis and increases cardiometabolic disease risk.
The Gut Bacteria That Put the Brakes on Weight Gain in Mice
December 16, 2025 / Gut Microbiome / Obesity Prevention / Metabolic Health / Turicibacter Bacteria / Weight Management
Researchers identified Turicibacter as a gut bacterium that reduces weight gain and improves metabolic health in mice on a high-fat diet. Lower levels of Turicibacter in humans with obesity suggest potential therapeutic roles in weight management.
Zealand links with China biotech in $20m metabolic discovery deal
December 18, 2025 / Metabolic Diseases / Obesity Drug Development / Zealand Pharma / Biotech Partnerships / Novel Therapeutics
Zealand Pharma and China’s OTR Therapeutics have partnered in a $20M+ deal to discover novel metabolic disease targets. The collaboration aligns with Zealand’s long-term strategy to advance obesity and metabolic therapies, with potential milestones reaching $2.5 billion.
Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy
December 17, 2024 / Obesity Treatment / Oral Weight Loss / Metabolic Health / Enveda Biotech / FDA IND Clearance
Enveda has initiated a Phase 1 trial for ENV-308, a first-in-class oral obesity therapy focused on durable weight loss with muscle preservation. FDA IND clearance and leadership expansion signal a strategic push toward long-term metabolic health solutions.
Obesity and work culture: Why India’s offices are the next frontline in metabolic health
December 21, 2025 / Workplace Obesity / Metabolic Health India / Employee Wellness / Corporate Stress Impact / Work-Life Balance
India’s demanding office culture is fueling a rise in obesity and metabolic diseases, highlighting the urgent need for structured workplace wellness programs that go beyond checklists and address stress, lifestyle habits, and mental health to improve long-term health outcomes.
High fructose intake increases fatty liver risk
December 16, 2025 / Fructose Intake / Fatty Liver Disease / NAFLD Risk / High Fructose Corn Syrup / Metabolic Syndrome
Excessive fructose intake, particularly from high‑fructose corn syrup, increases the risk of non‑alcoholic fatty liver disease by promoting hepatic fat accumulation, insulin resistance, and metabolic dysregulation, with potential long‑term and transgenerational metabolic effects.
MicroRNAs in Breastmilk of Overweight Mothers Reviewed
December 20, 2025 / Breastmilk MicroRNAs / Maternal Obesity / Infant Metabolism / EV-miRNA Function / Neonatal Health
Breastmilk from overweight mothers contains altered extracellular vesicle microRNAs (EV-miRNAs), which may impact infant immune, metabolic, and neurodevelopment by systemically regulating gene expression through stable, bioactive molecular signaling.
‘Thin-Fat’ Phenotype: Policy makers, doctors at Hyderabad AIG meet warn of obesity epidemic in India
December 18, 2025 / Thin-Fat Phenotype / Indian Obesity Epidemic / Visceral Fat Risk / Metabolic Syndrome India / Urban Lifestyle Health
India’s rising obesity epidemic is driven by the “Thin-Fat” phenotype—low BMI but high visceral fat—urbanization, processed diets, and workplace stress, increasing risk for metabolic syndrome and Type 2 diabetes even in individuals with normal weight.
Wegovy cleared in Canada to treat fatty liver disease MASH
December 22, 2025 / Wegovy Canada Approval / MASH Treatment Semaglutide / Fatty Liver Disease Therapy / GLP-1 Liver Fibrosis / Health Canada Obesity Drug
Health Canada has conditionally approved Wegovy (semaglutide) as the first treatment for MASH, showing significant benefits in reversing liver fibrosis and inflammation in patients with moderate to advanced liver scarring, pending further Phase 3 data for full approval.
Extracellular Vesicles Offer Insight into MASLD Development After Menopause
December 19, 2025 / MASLD Biomarkers Women / Extracellular Vesicles Liver / Postmenopause Fatty Liver / INHBE AFM Steatosis / Metabolic Dysfunction Menopause
TGen researchers identified extracellular vesicle proteins, particularly INHBE and AFM, as potential blood-based biomarkers for MASLD progression in postmenopausal women, offering insights into liver fat accumulation and early metabolic dysfunction after estrogen loss.
Novel Ultrasound Technology Can Maintain Accuracy in Liver Fat Assessment Despite Variations in Patient Breathing Patterns
December 19, 2025 / UGAP Ultrasound Liver / Hepatic Steatosis Detection / Liver Fat Assessment / Fibrosis Breath Variability / Noninvasive Liver Monitoring
UGAP ultrasound technology accurately measures liver fat content across different breathing phases, including in patients with liver fibrosis who cannot hold their breath, supporting its reliability in diverse clinical scenarios for hepatic steatosis assessment.
Pemvidutide Shows Continued Antifibrotic Activity for MASH, Progresses to Phase 3 Trial
December 19, 2025 / Pemvidutide MASH / Antifibrotic Therapy / GLP-1 Glucagon Agonist / Liver Fibrosis Trial / Phase 3 MASH Treatment
Pemvidutide demonstrated sustained antifibrotic and metabolic benefits in Phase 2b MASH patients, significantly improving noninvasive fibrosis markers, liver fat, and weight with good tolerability, supporting advancement into a registrational Phase 3 trial.
Galectin falls on MASH candidate belapectin update, additional $10M credit line
December 19, 2025 / Belapectin MASH / Galectin Therapeutics FDA / Liver Fibrosis Trial / Esophageal Varices Endoscopy / MASH Drug Development
Galectin Therapeutics plans a Type C FDA meeting to finalize its registrational trial for belapectin in MASH, despite previous trial failure; the company secured an additional $10M credit line to extend funding through March 2027.
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement
December 22, 2025 / BMN349 / AATD Liver Disease / BioMarin Pipeline Update / MASH Clinical Trial / Genetic Liver Disorder
BioMarin has discontinued development of BMN 349, its Phase 1 oral candidate for AATD-associated liver disease and MASH, citing strategic reprioritization—not safety or efficacy concerns—amid its $4.8B acquisition of Amicus.